2011
DOI: 10.1016/j.healun.2011.01.728
|View full text |Cite
|
Sign up to set email alerts
|

Usefulness of extracorporeal membrane oxygenation for early cardiac allograft dysfunction

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
43
0
2

Year Published

2014
2014
2020
2020

Publication Types

Select...
5
5

Relationship

1
9

Authors

Journals

citations
Cited by 82 publications
(50 citation statements)
references
References 21 publications
5
43
0
2
Order By: Relevance
“…Similarly, amongst post-surgical patients, those with ECMO after heart transplantation had the highest survival rate at 57.1% (95% CI 49.7–64.2) and were supported for a median of 108 hours (IQR 66–173). These results provide support to other reports of relatively good survival in this post-transplantation group [3133], and in this large dataset the survival was relatively good despite longer treatment than in other groups.…”
Section: Discussionsupporting
confidence: 91%
“…Similarly, amongst post-surgical patients, those with ECMO after heart transplantation had the highest survival rate at 57.1% (95% CI 49.7–64.2) and were supported for a median of 108 hours (IQR 66–173). These results provide support to other reports of relatively good survival in this post-transplantation group [3133], and in this large dataset the survival was relatively good despite longer treatment than in other groups.…”
Section: Discussionsupporting
confidence: 91%
“…[226][227][228][229][230][231][232][233][234][235] The majority of published data describe the relatively successful use of extracorporeal membrane oxygenation (ECMO) in cases of primary graft failure. Although 30-day mortality is reduced in those who receive ECMO, in those who survive 30 days, long-term survival appears to be comparable to those who do not have primary graft failure.…”
Section: Mechanical Circulatory Support In Amr With Hemodynamic Comprmentioning
confidence: 99%
“…Лечение острой дисфункции трансплантата ос-тается чрезвычайно сложной задачей, несмотря на проводимую интенсивную медикаментозную под-держку и широкое применение в последние годы циркуляторной поддержки (внутриаортальная бал-лонная контрпульсация, экстракорпоральная мем-бранная оксигенация (ЭКМО), системы механи-ческой поддержки сердца) [13,15]. В более легких случаях лечение ограничивается большими дозами инотропных препаратов, включая катехоламины, ингибиторы фосфодиэстеразы и левосимендан, применяемые до восстановления сократительной способности трансплантата [3,23].…”
Section: Discussionunclassified